血清ProGRP、CYFRA21-1、CEA在肺癌诊断中的临床价值研究OA
Study on the clinical value of serum ProGRP,Cyfra21-1 and CEA in the diagnosis of lung cancer
目的 探讨血清胃泌素释放肽前体(ProGRP)、细胞角蛋白19片段(CYFRA21-1)和癌胚抗原(CEA)在肺癌诊断中的临床应用价值.方法 选取2022年11月至2024年11月北京市鼓楼中医医院收治的肺癌患者168例作为肺癌组,另纳入同期50例肺部良性病变患者、50名健康体检者分别为良性组、健康组.比较肺癌组、良性组和健康组血清ProGRP、CYFRA21-1、CEA 水平;比较不同分期、不同病理类型肺癌患者的ProGRP、CYFRA21-1、CEA水平,采用受试者工作特征(ROC)曲线并计算曲线下面积(AUC)评估血清生物标志物诊断肺癌的价值.结果 与其他组相比,肺癌组血清ProGRP、CYFRA21-1、CEA 水平较高(P<0.05).相较于Ⅰ～Ⅱ期,Ⅲ～Ⅳ期患者血清ProGRP、CYFRA21-1、CEA水平较高(P<0.05).小细胞肺癌患者血清ProGRP水平高于非小细胞肺癌(P<0.05),CYFRA21-1、CEA低于非小细胞肺癌(P<0.05).在非小细胞肺癌亚型中,鳞癌患者 CYFRA21-1水平明显高于腺癌(P<0.05),而腺癌患者 CEA 水平明显高于鳞癌(P<0.05).血清ProGRP、CYFRA21-1、CEA 单独及联合检测诊断肺癌的 AUC分别为0.766、0.743、0.774和0.882(P<0.05).结论 血清ProGRP、CYFRA21-1、CEA联合检测在诊断肺癌中具有较高的临床应用价值.
Objective To explore the clinical application value of serum pro-gastrin-releasing peptide precursor(ProGRP),cytokeratin 19 fragment(CYFRA21-1),and carcinoembryonic antigen(CEA)in the di-agnosis of lung cancer.Methods From November 2022 to November 2024,168 lung cancer patients admitted to the Gulou Hospital of Traditional Chinese Medicine of Beijing were selected as the lung cancer group.An-other 50 patients with benign lung lesions and 50 healthy individuals undergoing physical examinations were included as the benign group and the healthy group respectively.The serum levels of ProGRP,CYFRA21-1 and CEA in the lung cancer group,the benign group and the healthy group were compared.The levels of Pro-GRP,CYFRA21-1 and CEA in lung cancer patients of different stages and different pathological types were al-so compared.The receiver operating characteristic(ROC)curve was used,and the area under the curve(AUC)was calculated to evaluate the value of serum biomarkers in diagnosing lung cancer.Results Com-pared with other groups,the levels of serum ProGRP,CYFRA21-1 and CEA in the lung cancer group were higher(P<0.05).Compared with patients in Ⅰ-Ⅱ stage,those in Ⅲ-Ⅳ stage had higher levels of serum ProGRP,CYFRA21-1 and CEA(P<0.05).The levels of serum ProGRP in small cell lung cancer patients were higher than those in non-small cell lung cancer(P<0.05),while the levels of CYFRA21-1 and CEA in small cell lung cancer patients were lower than those in non-small cell lung cancer patients(P<0.05).A-mong the non-small cell lung cancer subtypes,the level of CYFRA21-1 in squamous cell carcinoma patients was significantly higher than that in adenocarcinoma(P<0.05),while the level of CEA in adenocarcinoma patients was significantly higher than that in squamous cell carcinoma(P<0.05).The AUC values for the in-dividual and combined detection of serum ProGRP,CYFRA21-1 and CEA in diagnosing lung cancer were 0.766,0.743,0.774 and 0.882 respectively(P<0.05).Conclusion The combined detection of serum Pro-GRP,CYFRA21-1 and CEA levels has a high clinical application value in the diagnosis of lung cancer.
吴慧青;任占宝;崔翠莲;张鹤
北京市鼓楼中医医院检验科,北京 100009首都医科大学附属北京朝阳医院检验科,北京 100020应急总医院检验科,北京 100028北京市鼓楼中医医院检验科,北京 100009
医药卫生
胃泌素释放肽前体细胞角蛋白19片段癌胚抗原肺癌临床价值
gastrin-releasing peptide precursorcytokeratin 19 fragmentcarcinoembryonic antigenlung cancerclinical value
《重庆医学》 2026 (5)
1010-1014,5
评论